22.03.2026, 872 Zeichen

Marinomed: Marinomed Biotech has decided, due to a short-term need for capital, to increase its share capital by up to 459,985 new shares and to carry out a capital increase. The goal of the transaction is to generate gross proceeds of at least EUR 2 million for the company. The subscription price per new share has been set at EUR 14. Marinomed is also releasing preliminary and unaudited figures for the 2025 fiscal year. According to these figures, revenue rose to €7.7 million in 2025 (2024: €4.7 million). This includes an advance payment of €5 million from the sale of the Carragelose business. Other operating income of €19.5 million includes a restructuring gain of €18.9 million as well as the Austrian research grant. Net income amounts to 15.2 mn (vs. -15.4 mn in 2024).

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (19/03/2026)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #1148: ATX macht nach schlechten Politik-Signalen wieder gut, FACC gesucht, kein Sound of Silence beim Trading Volume

Bildnachweis

Aktien auf dem Radar:Mayr-Melnhof, Flughafen Wien, AT&S, Zumtobel, FACC, Lenzing, OMV, Polytec Group, Palfinger, Fabasoft, Rosgix, Bajaj Mobility AG, VIG, Bawag, Marinomed Biotech, Erste Group, Athos Immobilien, BTV AG, DO&CO, RBI, voestalpine, Wolftank-Adisa, Wiener Privatbank, Rosenbauer, Semperit, BKS Bank Stamm, Oberbank AG Stamm, Amag, CA Immo, EuroTeleSites AG, CPI Europe AG.

---